The FDA approves remibrutinib for symptomatic dermographism, the first such therapy, extending an oral BTK inhibitor label via the Phase III RemIND trial.
|Articles|July 1, 2001
- Pharmaceutical Technology-07-02-2001
- Volume 25
- Issue 7
Catching Up with Expert Systems
The pharmaceutical industry faces some roadblocks in terms of the implementation of expert systems. Principal among them are FDA's requirements for the submission of software codes.
Advertisement
Articles in this issue
over 25 years ago
Musings on the Past 25 Yearsover 25 years ago
Reflections on Changes at FDAover 25 years ago
Deliver the Doseover 25 years ago
Middle-European Pharmaceutics in a Changing Worldover 25 years ago
The BCS: Where Do We Go From Here?over 25 years ago
From Inactive Ingredients to Pharmaceutical Excipientsover 25 years ago
Am I Going Backwards?over 25 years ago
The Filter Scene: Old and Newover 25 years ago
25 Years of Change in the Parenteral Technology FieldAdvertisement
Related to this article
The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Shadow AI and vendor data retention put GMP records and trade secrets at risk. AI Pulse Check panelists outline what pharma AI policies require.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Advertisement
Advertisement